Aunt Minnie (11/1) reports that a new study in the Journal of the American College of Surgeons found that “surveillance is safe” for a type of high-risk breast “lesion called flat epithelial atypia” that is “typically treated surgically.” Researchers at Massachusetts General Hospital reviewed 208 patients’ medical records over a nine-year period. Senior author Dr. Constance Lehman said, “Surveillance, rather than surgery, is a good option for women with [flat epithelial atypia] lesions who do not have a genetic mutation and are not interested in chemoprevention.”
The Boston Globe (10/24, McCluskey) reports Massachusetts General Hospital recently “became the first US hospital to launch use of a new mammography system” developed by General Electric that “is designed to make the experience more comfortable” by using a “hand-held remote that allows patients – not the medical professional administering the test – to control the level of pressure they feel during the exam.” The FDA approved the device in September “after finding that it did not lead to lower-quality images or significantly increase exam times.”
Reuters (10/19, Harding) reports that “African-American women have worse breast cancer survival than white women in the US, and” research published in the Journal of Clinical Oncology “suggests that is largely because black women are less likely to have health insurance.” The research indicated approximately “23 percent of black women diagnosed with breast cancer in 2004-2013 had either no health insurance or had Medicaid coverage, versus 8 percent of white breast cancer patients.” This “insurance difference explained about 37 percent of the excess mortality among black women, the researchers calculated.”
Medscape (10/19, Harrison) reports, meanwhile, that “tumor characteristics accounted for 23.2% of the excess risk.”
Aunt Minnie (10/23) reports that the University of Virginia Health System is “enrolling women diagnosed with stage IV metastatic breast cancer in a new clinical trial that will combine two therapies: focused ultrasound and a cancer immunotherapy drug, according to the Focused Ultrasound Foundation.” The article adds that participants “will receive noninvasive focused ultrasound therapy using Theraclion’s EchoPulse system to ablate part of the primary breast tumor or metastatic tumors and also doses of pembrolizumab (Keytruda, Merck).” Dr. David Brenin, one of the leaders of the study, said, “Focused ultrasound induces a local immune response and may have the ability to change that paradigm, enabling a medication like pembrolizumab to make a difference.”
Aunt Minnie (10/12) reports that research indicates “employees at companies with fewer than 25 workers are less likely to be screened for cervical, breast, and colorectal cancer.” The findings were published online in Preventive Medicine.